Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ATNM | US
0.04
2.38%
Healthcare
Biotechnology
30/06/2024
17/10/2024
1.72
1.67
1.73
1.64
Actinium Pharmaceuticals Inc. a clinical-stage biopharmaceutical company develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes including Actinium-225 Iodine-131 and Lutetium-177 directed at multiple targets in oncology and hematology including CD45 CD33 HER3 and other. It has collaboration with Astellas Pharma Inc. to develop theranostics for solid tumor indications; EpicentRx Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York New York.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
81.5%1 month
66.2%3 months
154.9%6 months
119.2%-
6.84
1.28
0.04
0.02
-3.62
1.73K
-
-46.48M
53.59M
53.59M
-
-57.67K
-
-100.00
-87.96
5.97
6.32
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.38
Range1M
0.45
Range3M
7.31
Rel. volume
0.55
Price X volume
268.65K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
CEL-SCI Corporation | CVM | Biotechnology | 0.95 | 58.42M | -3.57% | n/a | 143.19% |
Allakos Inc | ALLK | Biotechnology | 0.65 | 57.75M | -1.28% | n/a | 47.30% |
CELU | CELU | Biotechnology | 2.6 | 57.16M | -6.47% | n/a | 159.71% |
Kronos Bio Inc | KRON | Biotechnology | 0.93 | 56.07M | -3.63% | n/a | 22.03% |
OncoCyte Corporation | OCX | Biotechnology | 3.12 | 53.39M | 0.32% | n/a | 16.15% |
Atara Biotherapeutics Inc | ATRA | Biotechnology | 9.38 | 53.22M | 1.96% | n/a | -81.03% |
Syros Pharmaceuticals Inc | SYRS | Biotechnology | 1.95 | 53.09M | 2.09% | n/a | -954.99% |
Aadi Bioscience Inc | AADI | Biotechnology | 2.15 | 52.92M | 0.47% | n/a | 1.34% |
Affimed N.V | AFMD | Biotechnology | 3.31 | 51.90M | -0.60% | n/a | 0.00% |
Elicio Therapeutics Inc. | ELTX | Biotechnology | 4.77 | 51.39M | 0.42% | 5.20 | -388.56% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.6 | 19.19M | 0.80% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 0.98 | 17.70M | -3.92% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5763 | 8.36M | -11.91% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2111 | 3.79M | 2.93% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.04 | 2.71M | -4.59% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0114 | 1.02M | 14.00% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.16 | 0 | -0.43% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.3 | 0 | 2.14% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.535 | 0 | 7.00% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.07 | 0 | 1.90% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -3.62 | 0.53 | Cheaper |
Ent. to Revenue | 1,726.07 | 4,005.99 | Cheaper |
PE Ratio | - | 40.42 | - |
Price to Book | 1.28 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 154.89 | 72.92 | Riskier |
Debt to Equity | 0.04 | -1.24 | Expensive |
Debt to Assets | 0.02 | 0.25 | Cheaper |
Market Cap | 53.59M | 3.78B | Emerging |